ロード中...
Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes
On October 27, 2015, talimogene laherparepvec (T-VEC), a first in class intralesional oncolytic virotherapy, was granted the US Food and Drug Administration approval for the treatment of melanoma in the skin and lymph nodes. Its approval has added yet another therapeutic option to the growing list o...
保存先:
| 出版年: | Oncolytic Virother |
|---|---|
| 第一著者: | |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5063497/ https://ncbi.nlm.nih.gov/pubmed/27785448 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OV.S99532 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|